, Tracking Stock Market Picks
Enter Symbol:
Anadys Pharmaceuticals, Inc. (ANDS) [hlAlert]

down 40.60 %

Anadys Pharmaceuticals, Inc. (ANDS) rated Outperform with price target $8 by Leerink Swann

Posted on: Friday,  Mar 20, 2009  9:25 AM ET by Leerink Swann

Leerink Swann rated Outperform Anadys Pharmaceuticals, Inc. (NASDAQ: ANDS) on 03/20/2009, when the stock price was $6.23.
Since then, Anadys Pharmaceuticals, Inc. has lost 40.61% as of 11/23/2011's recent price of $3.70.
If you would have followed this Leerink Swann 's recommendation on ANDS, you would have lost 40.6% of your investment in 978 days.

Anadys Pharmaceuticals, Inc., is a biopharmaceutical company committed to advancing patient care by discovering, developing and commercializing novel small molecule medicines for the treatment of viral diseases and cancer. The Company's programs focus on Toll-Like Receptor-based small molecule product candidates and direct antiviral compounds that inhibit key steps in viral proliferation. The Company has core expertise in medicinal chemistry coupled with structure-based drug design, and is developing compounds for the treatment of hepatitis C infection, hepatitis B infection and cancer.

Leerink Swann Equity Research provides unique perspectives and agenda-setting healthcare recommendations for investors. Supported by industry-based intelligence and thorough market examination, our proprietary research enables our clients to make well-informed healthcare investment decisions. Our investment perspectives are driven by proprietary insights from MEDACorp. MEDACorp's more than 25,000 network professionals work with new and/or development-stage pharmaceuticals, medical devices and biotherapeutics on a daily basis. MEDACorp's extensive knowledge of products and research enables Leerink Swann to provide growth-focused clients an expertise earned through experience.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
3/20/2009 9:25 AM Buy
6.23 8.00
as of 12/31/2009
1 Week down  -44.10 %
1 Month down  -44.10 %
3 Months down  -51.33 %
1 YTD down  -79.45 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy